文献速递类风湿关节炎

接受利妥昔单抗治疗的类风湿关节炎患者对两剂和三剂SARS-CoV-2疫苗的体液和细胞免疫应答:一项前瞻性队列研究

Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study.
PubMed 文献 · Lancet Rheumatol · 2021-12-23

在挪威两家医院开展的前瞻性队列研究(Nor-vaC)中,87例接受利妥昔单抗治疗的类风湿关节炎患者和1114名健康对照按挪威国家疫苗接种计划接种SARS-CoV-2疫苗。两剂后患者血清学应答率21.8%远低于对照的98.4%(p<0.0001);49例抗体不足者接种第三剂后8例(16.3%)出现血清学应答,但受检的12例均出现CD4+和CD8+ T细胞应答。作者认为第三剂可能不诱导血清学应答,但可考虑增强细胞免疫应答。

要点

  • 两剂疫苗后仅21.8%的利妥昔单抗治疗患者产生血清学应答,健康对照为98.4%(p<0.0001)。
  • 末次利妥昔单抗输注至接种时间(应答者中位267天 vs 无应答者107天)与疫苗类型和血清学应答显著相关。
  • 第三剂后8/49例(16.3%)产生血清学应答,受检12例均产生CD4+和CD8+ T细胞应答。

核心结论

  • 本研究揭示了接受利妥昔单抗治疗的类风湿关节炎患者对两剂和三剂SARS-CoV-2疫苗的体液与细胞免疫应答存在分离。
  • 作者认为,在利妥昔单抗输注后6-9个月接种第三剂疫苗可能不诱导血清学应答,但可考虑用于增强细胞免疫应答。

研究设计与样本

  • 前瞻性队列研究(Nor-vaC),在挪威两家医院开展,纳入接受利妥昔单抗治疗的类风湿关节炎患者和按挪威国家疫苗接种计划接种SARS-CoV-2疫苗的健康对照。
  • 对两剂后血清学应答不足(SARS-CoV-2刺突蛋白受体结合域抗体浓度<100 AU/mL)的患者分配第三剂疫苗。
  • 第二剂后2-4周及第三剂后检测血清抗RBD抗体;在一部分患者中于第二剂前、第二剂后7-10天及第三剂后3周采血,用刺突蛋白肽刺激冷冻保存的外周血单个核细胞评估T细胞应答。
  • 主要结局为接种两剂和三剂SARS-CoV-2疫苗后产生血清学应答(抗RBD抗体浓度≥70 AU/mL)和针对刺突肽T细胞应答的参与者比例。
  • 研究注册于ClinicalTrials.gov(NCT04798625),正在进行中。

主要发现

  • 2021年2月9日至2021年5月27日入组90例患者,其中87例提供血清并纳入分析(女性69例[79.3%],男性18例[20.7%]);纳入健康对照1114名(女性854名[76.7%],男性260名[23.3%])。
  • 49例患者被分配第三剂疫苗。
  • 两剂后,87例患者中19例(21.8%)产生血清学应答,1114名健康对照中1096名(98.4%)产生血清学应答(p<0.0001)。
  • 末次利妥昔单抗输注至接种时间(应答者中位267天[IQR 222-324] vs 无应答者107天[80-152])和疫苗类型(mRNA-1273 vs BNT162b2)与血清学应答显著相关(校正年龄和性别)。
  • 两剂后,19例患者中10例(53%)产生CD4+ T细胞应答,14例(74%)产生CD8+ T细胞应答。

关键数值与推荐

  • 血清学应答不足定义为抗SARS-CoV-2刺突蛋白受体结合域抗体浓度<100 AU/mL(用于分配第三剂)。
  • 血清学应答定义为抗RBD抗体浓度≥70 AU/mL。
  • 两剂后血清学应答率:患者19/87(21.8%)vs 健康对照1096/1114(98.4%)(p<0.0001)。
  • 第三剂后血清学应答率:8/49(16.3%);受检患者T细胞应答:CD4+和CD8+均为12/12。

临床怎么用

  • 作者认为,在利妥昔单抗输注后6-9个月接种第三剂疫苗可能不诱导血清学应答,但可考虑用于增强细胞免疫应答。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In rituximab-treated patients with rheumatoid arthritis, humoral and cellular immune responses after two or three doses of SARS-CoV-2 vaccines are not well characterised. We aimed to address this knowledge gap. METHODS: This prospective, cohort study (Nor-vaC) was done at two hospitals in Norway. For this sub-study, we enrolled patients with rheumatoid arthritis on rituximab treatment and healthy controls who received SARS-CoV-2 vaccines according to the Norwegian national vaccination programme. Patients with insufficient serological responses to two doses (antibody to the receptor-binding domain [RBD] of the SARS-CoV-2 spike protein concentration <100 arbitrary units [AU]/mL) were allotted a third vaccine dose. Antibodies to the RBD of the SARS-CoV-2 spike protein were measured in serum 2-4 weeks after the second and third doses. Vaccine-elicited T-cell responses were assessed in vitro using blood samples taken before and 7-10 days after the second dose and 3 weeks after the third dose from a subset of patients by stimulating cryopreserved peripheral blood mononuclear cells with spike protein peptides. The main outcomes were the proportions of participants with serological responses (anti-RBD antibody concentrations of ≥70 AU/mL) and T-cell responses to spike peptides following two and three doses of SARS-CoV-2 vaccines. The study is registered at ClinicalTrials.gov, NCT04798625, and is ongoing. FINDINGS: Between Feb 9, 2021, and May 27, 2021, 90 patients were enrolled, 87 of whom donated serum and were included in our analyses (69 [79·3%] women and 18 [20·7%] men). 1114 healthy controls were included (854 [76·7%] women and 260 [23·3%] men). 49 patients were allotted a third vaccine dose. 19 (21·8%) of 87 patients, compared with 1096 (98·4%) of 1114 healthy controls, had a serological response after two doses (p<0·0001). Time since last rituximab infusion (median 267 days [IQR 222-324] in responders vs 107 days [80-152] in non-responders) and vaccine type (mRNA-1273 vs BNT162b2) were significantly associated with serological response (adjusting for age and sex). After two doses, 10 (53%) of 19 patients had CD4+ T-cell responses and 14 (74%) had CD8+ T-cell responses. A third vaccine dose induced serological responses in eight (16·3%) of 49 patients, but induced CD4+ and CD8+ T-cell responses in all patients assessed (n=12), including responses to the SARS-CoV-2 delta variant (B.1.617.2). Adverse events were reported in 32 (48%) of 67 patients and in 191 (78%) of 244 healthy controls after two doses, with the frequency not increasing after the third dose. There were no serious adverse events or deaths. INTERPRETATION: This study provides important insight into the divergent humoral and cellular responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis. A third vaccine dose given 6-9 months after a rituximab infusion might not induce a serological response, but could be considered to boost the cellular immune response. FUNDING: The Coalition for Epidemic Preparedness Innovations, Research Council of Norway Covid, the KG Jebsen Foundation, Oslo University Hospital, the University of Oslo, the South-Eastern Norway Regional Health Authority, Dr Trygve Gythfeldt og frues forskningsfond, the Karin Fossum Foundation, and the Research Foundation at Diakonhjemmet Hospital.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Jyssum I, Kared H, Tran TT, et al. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. Lancet Rheumatol. 2021. PMID: 34977602. doi:10.1016/S2665-9913(21)00394-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。